Actively Recruiting
Study of Romiplostim N01 With Glucocorticoids as First Treatment for Adults Newly Diagnosed With Primary Immune Thrombocytopenia ITP
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-05-28
129
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of romiplostim N01 combined with glucocorticoids as a first treatment for adults newly diagnosed with primary immune thrombocytopenia ITP. This prospective, multicenter, randomized trial involves adults aged 18 to 75 who have not received prior ITP treatment and aims to assess continuous remission after six months of treatment. Participants are randomly assigned in a 21 ratio to either receive romiplostim N01 plus glucocorticoids or glucocorticoids alone. The glucocorticoid used is dexamethasone at 40 mg per day for four days, repeated once if no response by day 10. Romiplostim N01 is administered as a weekly subcutaneous injection starting at 3 gkg, with dose adjustments based on platelet counts over up to six months. Follow-up continues up to 24 weeks after treatment ends. During the study, participants will have their platelet counts, bleeding symptoms, and side effects monitored regularly. Researchers will track adverse events, medications, and treatments throughout the trial. The main outcome is the proportion of patients who achieve continuous remission at six months, along with other measures like response rates at one, three, six, nine, and twelve months, bleeding severity, and safety data.
CONDITIONS
Brief Title
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
Research Team
L
Lei Zhang
Y
Yunfei Chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here